combination therapy

John Gribben’s ASH 2019 CLL and lymphoma highlights

John Gribben’s ASH 2019 CLL and lymphoma highlights

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals

Marina Konopleva • 8 Dec 2019

Developing mantle cell lymphoma treatment for further success

Developing mantle cell lymphoma treatment for further success

Update on selinexor for myeloma and large cell lymphomas

Update on selinexor for myeloma and large cell lymphomas

MRD in the immuno-chemo era

MRD in the immuno-chemo era

Florence Cymbalista • 22 Sep 2019

MURANO: outcomes after the end of treatment

MURANO: outcomes after the end of treatment

John Seymour • 22 Sep 2019

CLL treatment: statistical analysis in predictive medicine

CLL treatment: statistical analysis in predictive medicine

Kevin Coombes • 22 Sep 2019

Comparing CLL regimens with MRD

Comparing CLL regimens with MRD

John Seymour • 22 Sep 2019

Predicting suboptimal response through intermediate MRD

Predicting suboptimal response through intermediate MRD

Andrew Rawstron • 22 Sep 2019

Novel combination therapies in CLL

Novel combination therapies in CLL

Matthew Davids • 22 Sep 2019

Will cellular therapy have a role in CLL in 2020?

Will cellular therapy have a role in CLL in 2020?

Anna Schuh • 22 Sep 2019

Venetoclax phase III trial disappointment

Venetoclax phase III trial disappointment

Lawrence Boise • 12 Sep 2019

Jarrod Longcor: ESMO highlights

Jarrod Longcor: ESMO highlights

Jarrod Longcor • 28 Sep 2019

Proof of principle to progress treatments

Proof of principle to progress treatments

Jonathan Keats • 13 Sep 2019

Myeloma tackling combinations

Myeloma tackling combinations

Enrique Ocio • 13 Sep 2019

Will knowledge of the molecular pathology of lymphoma improve clinical trials?

Will knowledge of the molecular pathology of lymphoma improve clinical trials?

David Maloney et al.

1
2
3
4
5
…
22
Next